Prevalence of sickle cell trait and sickle cell disease among African American live births in Shelby Co., TN
Accurate regional quantification of sickle cell disease (SCD) and sickle cell trait (SCT) in the U.S. could aid public health officials and clinicians to better allocate and prioritize resources. The CDC estimates SCD and SCT at 1/500 and 1/12 African American (AA) live births and multiple sources suggest SCD rates could be as high as 1/350. From statewide newborn screening, positive tests for hemoglobinopathies in Shelby County Tennessee are reported to St. Jude Children's Research Hospital in Memphis. Using data from 2002-2010, we estimated the prevalence of SCD and SCT and compared rates to the national averages. In Shelby County, SCT was found in 5,146/75,784 AA live births and SCD in 267/75,784. The SCT prevalence was 67.9 (95% CI: 66.1-69.7)/1000 AA births, approximately 1/14.7. That rate for SCT is lower than the nationally reported 1/12 live births (p-value<0.001). The prevalence of SCD was 3.5 (95% CI: 3.1-4.0)/1000 AA live births or 1/286 (60% HbSS/Sβ0 thalassemia), which is higher than the national estimate of 1/350 (p-value<0.001). Our SCT findings were similar to those of a California study that found 1/14 AA births but our SCD rates differed from the 1/396 (57% HbSS/Sβ0 thalassemia) found in the same California study. Recent Shelby County rates of SCD and SCT differ substantially from national averages with higher than expected SCD and lower than expected SCT rates, warranting further investigation. We have demonstrated that variation in SCD and SCT rates exists in the U.S. and suggest that regional studies would better inform screening, education, and health care resource allocation.
Describe the prevalance of sickle cell trait and sickle cell diesease among African American live births in Shelby Co., TN and compare with national rates.
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am the first author's PhD faculty advisor and have worked closely with him to conduct this study and interpret the findings.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.